The value of PSMA PET for risk stratification in prostate cancer: an update and future aspects.

PSMA-PET has become a pivotal imaging method for staging and restaging of prostate cancer. Risk stratification of the disease is a crucial for the patients to receive most appropriate treatment, and for the clinicians to follow the patients more precisely. PSMA-PET provides non-invasive biomarkers for the risk assessment of prostate cancer, offering prediction of clinical outcomes. PROMISE criteria have been developed as comprehensive and integrated framework demonstrating association with overall survival. In this review, we aim to provide a brief update of the prognostic value of PSMA-PET for risk assessment in prostate cancer.